CFDE Data Portal | Search MRPS9-AS1

	Label	Description
	MRPS9-AS1 Gene (Entity type)	ENSG00000231851 - MRPS9 antisense RNA 1
	GSE265788 IDH1 inhibition RNA-Directed DNA Polymerase 3 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE252944 AKT inhibition 10 v 15 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE128730 3 V 5 NERATINIB HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE261563 CX-5461 6 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE212330 azacitidine 1 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE125862 2 V 1 DEXAMETHASONE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE119369 H10 inhibition 1 v 5 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE196035 GSE196037 MEN1 inhibition 6 v 10 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE195568 palbociclib 1 v 10 human up Gene Set (Entity type)	A Gene Set from LINCS

MRPS9-AS1

ENSG00000231851 - MRPS9 antisense RNA 1

GSE265788 IDH1 inhibition RNA-Directed DNA Polymerase 3 v 2 human dn

A Gene Set from LINCS

GSE252944 AKT inhibition 10 v 15 human dn

A Gene Set from LINCS

GSE128730 3 V 5 NERATINIB HUMAN UP

A Gene Set from LINCS

GSE261563 CX-5461 6 v 1 human up

A Gene Set from LINCS

GSE212330 azacitidine 1 v 0 human dn

A Gene Set from LINCS

GSE125862 2 V 1 DEXAMETHASONE HUMAN UP

A Gene Set from LINCS

GSE119369 H10 inhibition 1 v 5 human up

A Gene Set from LINCS

GSE196035 GSE196037 MEN1 inhibition 6 v 10 human up

A Gene Set from LINCS

GSE195568 palbociclib 1 v 10 human up

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.